BEAM vs NTLA
BEAM and NTLA side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BEAMBeam Therapeutics Inc. | NTLAINTELLIA THERAPEUTICS, INC. |
|---|---|---|
| Market cap | $2.40B | $1.59B |
| P/B | 2.25 | — |
| P/S | 17.2x | 23.6x |
| Revenue | $156.03M(TTM) | — |
| Revenue growth (YoY) | 120.0% | 16.9% |
| Net income | -$86.52M(TTM) | — |
| Earnings growth (YoY) | 78.8% | 20.5% |
| EPS, diluted | $-0.69(TTM) | — |
| EBIT margin | -274.6% | -651.7% |
| ROE | -7.5% | -56.7% |
| ROIC | -40.5% | — |
| 1y total return | +9.3% | -1.6% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: BEAM vs NTLA
| Metric | BEAM | NTLA |
|---|---|---|
| End value | $12.4K | $8.0K |
| Total return | +23.8% | -19.7% |
| CAGR | +3.3% | -3.3% |
| Volatility | 79.9% | 83.3% |
| Sharpe | 0.38 | 0.33 |
| Sortino | 0.59 | 0.49 |
| Max drawdown | -89.1% | -96.5% |
Based on 1660 common trading days, 2020-02-06 → 2026-09-15 · risk-free 4.11% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)